[2] Rudolph M, Anzeneder T, Schulz A, et al. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection[J]. BMC cancer, 2016, 16: 622. [3] Xiao W, Z...
4. Rudolph M, Anzeneder T, Schulz A, Beckmann G, Byrne AT, Jeffers M, Pena C, Politz O, Köchert K, Vonk R, Reischl J. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterat...
Breast cancerLiquid biopsyProficiency testingAlpelisibPrecision oncology based on specific molecular alterations requires precise and reliable detection of therapeutic targets in order to initiate the optimal treatment. In many European countries鈥攊ncluding Germany鈥攁ssays employed...
Request Your Free Guide: Everything You Need to Know About PIK3CA Mutation Testing in 2 Minutes The PIK3CA pathway is one of the most frequently altered pathways in human cancers, especially in breast cancer. Many mutations in the PIK3CA gene have been shown to be oncogenic, representing an ...
In one case, while the druggable mutation p.H1047R was detected through tissue testing, the corresponding plasma analysis showed a wild-type PIK3CA status. Conclusion: In metastatic HR+/HER2- breast cancer, PIK3CA testing is more frequently performed on tissue samples. Liquid biopsies provide a ...
Importantly, targeted inhibition of the check-point inhibitor CHK1 with MK-8776 effectively caused death of p21-high T47D cells, thus establishing a new vulnerability of BYL719-resistant breast cancer cells. Together, our integrated studies uncover hidden molecular mediators causing resistance to PI3K...
Subsequently, we selected two immortalized breast epithelial cell lines and seven different breast cancer cell lines with relatively high p110α expression levels for efficacy testing using the SRB assay. Notably, ER + T47D and HER2+ BT474 displayed greater sensitivity to PI3K PROTAC Discussion ...
With the approval of new therapies targeting the PI3K pathway, the detection of PIK3CA mutations has become a key factor in treatment management for HR+/HER2− metastatic breast cancer (MBC). We developed multiplex digital PCR (dPCR) assays to detect and quantify PIK3CA mutations. A first scr...
which is a huge step forward for advanced breast cancer patients with aPIK3CAmutation,” said Jean Sachs, CEO of Living Beyond Breast Cancer. “It remains critical that all patients have access to early, comprehensive biomarker testing so they can better understand what treatment options may be ...
1 PIK3CA is the most commonly mutated gene in hormone-receptor positive, HER2-negative breast cancer, with approximately 40% of patients harboring this mutation.2 “This approval reinforces the importance of testing for PIK3CA mutations at the time of diagnosis to help guide decision-making in ...